Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy
Allergen immunotherapy (AIT) with aeroallergens is the only disease-modifying treatment for patients with different allergic conditions. Despite the effectiveness of AIT having been proven in both randomized controlled trials and real-world studies, it remains underused in less than 10% of subjects...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Current Issues in Molecular Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1467-3045/45/12/623 |
| _version_ | 1797381603937222656 |
|---|---|
| author | Ruperto González-Pérez Paloma Poza-Guedes Fernando Pineda Inmaculada Sánchez-Machín |
| author_facet | Ruperto González-Pérez Paloma Poza-Guedes Fernando Pineda Inmaculada Sánchez-Machín |
| author_sort | Ruperto González-Pérez |
| collection | DOAJ |
| description | Allergen immunotherapy (AIT) with aeroallergens is the only disease-modifying treatment for patients with different allergic conditions. Despite the effectiveness of AIT having been proven in both randomized controlled trials and real-world studies, it remains underused in less than 10% of subjects with allergic rhinitis (AR) and/or asthma (A). We aimed to determine the current eligibility for house dust mite (HDM) AIT by means of a precision allergy molecular diagnosis (PAMD@) model in a selected cohort of youngsters with different allergic phenotypes according to the available evidence. A complex response to both HDM and storage mite allergens was depicted regardless of the subjects’ basal atopic condition. No solely specific IgE-binding responses to Der p 1, Der p 2, and/or Der p 23 were found in the studied cohort. Despite the patients with A and atopic dermatitis showing significantly higher serum titers to six mite allergens than subjects with AR, no specific molecular profile was regarded as disease specific. Given the increasing complexity of specific IgE responses to the local prevailing aeroallergens, the identification and presence of such molecules are needed in commercially available AIT in the era of precision medicine. |
| first_indexed | 2024-03-08T20:53:48Z |
| format | Article |
| id | doaj.art-851c914001cf4515ba39a5cd3c6a9a6e |
| institution | Directory Open Access Journal |
| issn | 1467-3037 1467-3045 |
| language | English |
| last_indexed | 2024-03-08T20:53:48Z |
| publishDate | 2023-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Issues in Molecular Biology |
| spelling | doaj.art-851c914001cf4515ba39a5cd3c6a9a6e2023-12-22T14:00:43ZengMDPI AGCurrent Issues in Molecular Biology1467-30371467-30452023-12-0145129976998410.3390/cimb45120623Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen ImmunotherapyRuperto González-Pérez0Paloma Poza-Guedes1Fernando Pineda2Inmaculada Sánchez-Machín3Allergy Department, Hospital Universitario de Canarias, 38320 Tenerife, SpainAllergy Department, Hospital Universitario de Canarias, 38320 Tenerife, SpainInmunotek SL Laboratories, 28805 Madrid, SpainAllergy Department, Hospital Universitario de Canarias, 38320 Tenerife, SpainAllergen immunotherapy (AIT) with aeroallergens is the only disease-modifying treatment for patients with different allergic conditions. Despite the effectiveness of AIT having been proven in both randomized controlled trials and real-world studies, it remains underused in less than 10% of subjects with allergic rhinitis (AR) and/or asthma (A). We aimed to determine the current eligibility for house dust mite (HDM) AIT by means of a precision allergy molecular diagnosis (PAMD@) model in a selected cohort of youngsters with different allergic phenotypes according to the available evidence. A complex response to both HDM and storage mite allergens was depicted regardless of the subjects’ basal atopic condition. No solely specific IgE-binding responses to Der p 1, Der p 2, and/or Der p 23 were found in the studied cohort. Despite the patients with A and atopic dermatitis showing significantly higher serum titers to six mite allergens than subjects with AR, no specific molecular profile was regarded as disease specific. Given the increasing complexity of specific IgE responses to the local prevailing aeroallergens, the identification and presence of such molecules are needed in commercially available AIT in the era of precision medicine.https://www.mdpi.com/1467-3045/45/12/623mitesallergen immunotherapymolecular allergologyallergensallergic phenotype |
| spellingShingle | Ruperto González-Pérez Paloma Poza-Guedes Fernando Pineda Inmaculada Sánchez-Machín Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy Current Issues in Molecular Biology mites allergen immunotherapy molecular allergology allergens allergic phenotype |
| title | Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy |
| title_full | Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy |
| title_fullStr | Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy |
| title_full_unstemmed | Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy |
| title_short | Advocacy of Precision Allergy Molecular Diagnosis in Decision Making for the Eligibility of Customized Allergen Immunotherapy |
| title_sort | advocacy of precision allergy molecular diagnosis in decision making for the eligibility of customized allergen immunotherapy |
| topic | mites allergen immunotherapy molecular allergology allergens allergic phenotype |
| url | https://www.mdpi.com/1467-3045/45/12/623 |
| work_keys_str_mv | AT rupertogonzalezperez advocacyofprecisionallergymoleculardiagnosisindecisionmakingfortheeligibilityofcustomizedallergenimmunotherapy AT palomapozaguedes advocacyofprecisionallergymoleculardiagnosisindecisionmakingfortheeligibilityofcustomizedallergenimmunotherapy AT fernandopineda advocacyofprecisionallergymoleculardiagnosisindecisionmakingfortheeligibilityofcustomizedallergenimmunotherapy AT inmaculadasanchezmachin advocacyofprecisionallergymoleculardiagnosisindecisionmakingfortheeligibilityofcustomizedallergenimmunotherapy |